Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEACH: Tafenoquine in Pediatric P. vivax Malaria
NCT02563496Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tafenoquine in Plasmodium vivax malaria (5 arms), sponsored by GSK. Primary endpoint: Area Under the Curve From Time 0 Extrapolated to Infinite Time at Day 60. Started Feb 2017; status: completed.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT02563496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563496.